Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Targeted therapy, particularly kinase inhibitors, is a rapidly advancing field in cancer treatment.
• These drugs offer efficacy in various malignancies with fewer side effects than traditional chemotherapy.
• However, kinase inhibitors can affect normal physiological functions due to shared kinase targets.

Purpose of the Study:

• To review the side effects of kinase inhibitors on blood platelet function.
• To discuss the impact on hemostasis and bleeding risk.
• To explore implications for patients on antithrombotic medications.

Main Methods:

• Literature review focusing on kinase inhibitors and their effects on platelet activation.
• Analysis of reported clinical data and preclinical studies.
• Discussion of known and emerging kinase inhibitors impacting platelet function.

Main Results:

• Several kinase inhibitors, such as dasatinib and ibrutinib, are known to impair platelet activation.
• These effects can lead to an increased risk of bleeding.
• The clinical significance is heightened in patients concurrently using antithrombotic agents.

Conclusions:

• Kinase inhibitors can interfere with critical platelet functions, including adhesion and aggregation.
• Understanding these side effects is crucial for managing patient safety and optimizing treatment strategies.
• Further research is needed for kinase inhibitors in development that may also affect platelet hemostatic functions.